Insulin delivery by injection in children and adolescents with diabetes by Hanas, R. et al.
Pediatric Diabetes 2011: 12: 518–526
doi: 10.1111/j.1399-5448.2010.00731.x
All rights reserved
© 2011 John Wiley & Sons A/S
Pediatric Diabetes
Review Article
Insulin delivery by injection in children
and adolescents with diabetes
Hanas R, de Beaufort C, Hoey H, Anderson B. Insulin delivery by injection
in children and adolescents with diabetes.
Pediatric Diabetes 2011: 12: 518–526.
Type 1 diabetes is treated with insulin, which has traditionally been
delivered by vial and syringe. However, for many patients, dosing
inaccuracy, pain, anxiety, inconvenience, and social acceptability present
barriers to this method of administration (1–5). This has contributed to
the increased popularity of alternative insulin delivery systems, including
pen delivery devices (4, 6).
Evidence suggests that discreet devices, such as insulin pens, facilitate
adherence to intensive insulin therapy regimens, help improve lifestyle
flexibility, and reduce injection pain compared with the conventional
syringe-based regimens, as shown in studies in adults and adolescents (7).
In addition, compared with the vial and syringe method of insulin admin-
istration, pens may provide more accurate dosing – which is particularly
important in children – thereby improving short-term blood glucose con-
trol and potentially improving long-term outcomes (5, 8). Children, in
particular, may benefit from insulin pens that are simple to use as adher-
ence issues may be more evident in this patient group (9). Pens for insulin
delivery in children with type 1 diabetes have been used for a long time
in Europe, and have recently gained in popularity in many other places
around the world (4, 10). Furthermore, the conventional vial and syringe
method of insulin delivery is beginning to be considered as obsolete (11).
Moreover, there is a continued drive to improve insulin pen technology, to
refine and enhance the functionality and usability of these pens. However,
despite recent advances in pen design and function, the selection of pens
available especially for children is limited.
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This review will explore the features of the available
insulin pens and consider how these may address the
needs of the paediatric population.
Features and benefits of insulin pens
Modern insulin delivery devices have numerous ad-
vantages compared with traditional vials and syringes.
Notably, insulin pens have been found to be easier
to use and transport, provide more accurate dosing,
reduce the fear associated with needles, reduce injec-
tion pain when used with the short, fine (5–6 mm and
30–32 gauge) needles, and reduce the embarrassment
of injecting in public (1, 4, 5, 8, 12–16). Furthermore,
insulin pens are associated with patient preference
and improved adherence compared with the vial and
syringe method of insulin delivery (4). In a study con-
ducted in the USA, Lee et al. (14) investigated the
impact on medication adherence when converting from
the vial and syringe method of insulin administration to
FlexPen® (Novo Nordisk A/S, Bagsværd, Denmark),
a prefilled insulin pen, in 1156 adult patients with type
2 diabetes. Adherence was measured by a medication
possession ratio (MPR; denoting the proportion of
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time a patient had a supply of medication during the
follow-up period) ≥80%. MPR values of <80% are
frequently used in the literature on chronic diseases
to define poor adherence to medication. Medication
adherence significantly improved after switching to
insulin pen devices (from 62% with vials and syringes to
69% with insulin pens, p < 0.01). In addition, the pro-
portion of patients who were adherent (MPR ≥80%)
was significantly higher after switching to insulin pens
compared with before (54.6% vs. 36.1%, respectively,
p < 0.01), indicating that switching from vials/syringes
to insulin pens improves medication adherence.
The first insulin pen device, NovoPen® (Novo
Nordisk A/S), was launched in 1985 and revolutionised
insulin administration for people with diabetes. Cur-
rent pen device manufacturers include Berlin-Chemie
AG, Eli Lilly and Company, Novo Nordisk A/S,
Owen Mumford Ltd, and Sanofi-Aventis. Since the
mid-1980s, insulin pens have evolved into more sophis-
ticated devices. Some pens have specific features such
as dose delivery confirmation (an audible click). This
reduces the potential for dosing errors and also alerts
visually impaired individuals to the insulin dose being
dialled, allowing them continued independence (17).
Modern pens also have dose selectors with dial-up/
down features that allow easy adjustment or correc-
tion of dialled doses. Moreover, the dose selectors are
designed in an ergonomic fashion, with different tex-
tures to fit better in the hand and ensure ease of use (17).
In 2007, the first insulin pen with a memory func-
tion, HumaPen® Memoir™ (Eli Lilly and Company,
Indianapolis, IN, USA) was launched. The memory
function addresses the common issue of anxiety over a
missed dose (18).
Insulin pens are constantly being developed in order
to improve their usability, potentially simplifying the
management of diabetes. They may be durable (i.e., the
insulin cartridge is replaceable) and larger cartridges
have been designed to reduce the number of cartridge
replacements required. In addition, disposable insulin
pens have been produced for individuals who have
difficulty in changing the cartridges (17, 19, 20).
Other benefits of insulin pen devices include the
discreet appearance, ease with which patients can learn
to use them, and the resulting user confidence (17).
These features may help to improve the quality of life
of people with diabetes, particularly in the paediatric
setting (Table 1) (21).
Use of insulin pens in the paediatric
population
The Diabetes Attitudes, Wishes, and Needs (DAWN)
Youth Survey, initiated by Novo Nordisk in cooper-
ation with the International Diabetes Federation, was
conducted between 2007 and 2008 to investigate the
Table 1. Insulin pen features
Key features of insulin pens for the management of diabetes
Long-term feasibility of MDI (40)
More convenient and easier to transport than traditional
vial/syringe (14, 21)
More accurate doses/greater precision (4, 5, 13)
Easier to use for those with visual or fine motor-skill
impairments (17)
Less injection-site pain (21)
May be used discreetly in public (4, 21)
Slim, lightweight, and ‘stylish’ design (17)
Helps improve lifestyle flexibility (4, 21)
Improves quality of life (21)
MDI, multiple daily injections.
effect of diabetes on the lives of children, adolescents,
and their families living with diabetes. In total, 60% of
children with diabetes were reported as not managing
their diabetes successfully at school, whilst children
with adequate support from their school had a better
quality of life and were less burdened by their con-
dition (22). In practice, schools may fail to train staff
in diabetes care and there may be a widespread lack
of legislative effort in most countries to ensure equal
and safe access to education for children with diabetes
(23). Evidently, social support from multiple domains
is very important for children with diabetes. Consid-
eration of the process by which diabetes is managed,
namely insulin delivery, is also integral to improving
quality of life. It is noteworthy that it may be easier
to train school staff to use insulin pens rather than
vials and syringes, which may aid in facilitating the
management of diabetes at school or in day care for
the very young child living with diabetes.
Adherence to insulin therapy is an important issue
in children and adolescents with diabetes (9). There is
evidence to show that some children and adolescents
develop ketoacidosis as a result of poor adherence to
insulin therapy (24, 25). The level and need for self-care
also differs with age; children with diabetes who were
diagnosed at an older age have been reported to have
more success with self-care (22). The consequences
of forgetting or omitting doses of insulin may lead
to a deterioration of metabolic control and include
increasing levels of haemoglobin (Hb)A1c (26, 27),
which lead to an increased risk of diabetes-related
complications. There is a need to improve self-care in
children and adolescents as long-term poor metabolic
control will increase the risk of diabetic complications
and cardiovascular disease (28, 29).
A study of children and adolescents with type 1
diabetes investigated their attitudes towards insulin
injections, needle phobia, and the experience of pain
when using different types of insulin devices. Study
participants (n = 158) answered a questionnaire using
Visual Analogue Scale (VAS) scores for various
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Table 2. Comparison of insulin pens commonly used in children with diabetes
Device Manufacturer
Memory
function
Dose increments
(units)
Choice of
colours
Ability to
customise pen
AutoPen® Junior Owen Mumford, Oxford, UK No 1.0 Yes No
ClikSTAR® Sanofi-Aventis, Paris, France No 1.0 Yes Yes
FlexPen®§ Novo Nordisk A/S, Bagsværd, Denmark No 1.0 No* No
HumaPen® Luxura™ Eli Lilly and Company, Indianapolis, IN,
USA
No 1.0 Yes No
HumaPen® Luxura™
HD**
Eli Lilly and Company, Indianapolis, IN,
USA
No 0.5 No No
HumaPen® Memoir™ Eli Lilly and Company, Indianapolis, IN,
USA
Yes 1.0 No No
KwikPen™§ Eli Lilly and Company, Indianapolis, IN,
USA
No 1.0 No No
NovoPen 3 Demi® Novo Nordisk A/S, Bagsvaerd, Denmark No 0.5 No No
NovoPen® 4 Novo Nordisk A/S, Bagsvaerd, Denmark No 1.0 No No
NovoPen Echo®** Novo Nordisk A/S, Bagsværd, Denmark Yes 0.5 Yes Yes
NovoPen® Junior Novo Nordisk A/S, Bagsværd, Denmark No 0.5 Yes No
SoloStar®§ Sanofi-Aventis, Paris, France No 1.0 No* No
*Different color depending on type of insulin.
§Prefilled, disposable pens (not for reuse).
**Manufacturer assures accuracy from 0.5 U dosing.
statements including injection pain and needle phobia.
The median VAS score of injection pain/fear was
rated lower with insulin pens than with syringes.
A total of 8.3% of the subjects scored themselves as
having pronounced needle phobia (1). Insulin pens
may therefore be preferable and help to facilitate
adherence in the paediatric population as they were
found to cause less fear and less injection pain than
syringes in this study. Today, pen device needles are
available in 4–6 mm lengths (30), while the shortest
syringe needle is 8 mm (5). The pen needles are also
thinner than syringe needles; the gauge of syringe
needles is usually 30 (0.30 mm) (5), while pen needles
designed for the paediatric population are available in
31 or 32 (0.25 or 0.23 mm) gauge (31).
There are several insulin pens available, in both
disposable and durable forms, that are commonly
used for insulin delivery in children with diabetes
(Table 2). An automatic injection device [Penmate®
(Novo Nordisk A/S)] in which a pen injector is used
has been shown to decrease insertion pain (32).
Numerous crossover comparison studies of insulin
pens have been conducted in adult patients (20, 33–38)
and although there has been a widespread acceptance
of insulin pens among both adults and children (10),
there are fewer comparative studies in children.
A select number of studies over the last decade have
explored the advantages of insulin pens in children
(39). The long-term feasibility of multiple daily injec-
tions (MDI; before meals) with insulin pens in children
Correction added after online publication 27 July 2011: corrections
have been made on the table to complete data on insulin pens and
manufacturers.
and adolescents has been demonstrated (40), and a later
study by Lteif and Schwenk (41) showed that insulin
pens are more accurate than syringes at delivering low
insulin doses in children with type 1 diabetes. Results
from the Diabetes Control and Complications Trial
(only vials/syringes were used in this study) (42) and
the UK Prospective Diabetes Study (28) highlight the
importance of striving to achieve and maintain the best
possible glycaemic control. Insulin pens potentially
offer substantial improvements in convenience, free-
dom, and flexibility for children and adults with
diabetes (43). Indeed, children are a key treatment
group and, as such, developing pens with this patient
population in mind is crucial.
Memory function
Despite the recent advances in insulin pen technology,
there are currently no insulin pens available with
memory functions that have been designed specifically
for the paediatric population. Forgetfulness can hinder
treatment adherence in children and adolescents with
diabetes; therefore, an insulin pen with a memory
function would be beneficial to this patient population.
Currently, HumaPen Memoir is the only insulin pen
available with a memory function; it records the 16
most recent doses administered. The functionality and
acceptability of HumaPen Memoir was investigated
in a multicentre, open-label, single-arm study lasting
6–10 wk involving adult patients with type 1 or type 2
diabetes (n = 290) and healthcare professionals (HCPs;
n = 16). The study participants rated the memory
function of HumaPen Memoir as important. When
520 Pediatric Diabetes 2011: 12: 518–526
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asked to select two aspects of the memory function
they considered to be most important, patients and
HCPs chose the ability to confirm that an injection had
been taken (55 and 63%, respectively), the ability to
view the number of units of the previous insulin dose
(38 and 44%, respectively), and the ability to check
when the previous insulin dose was taken (25 and 44%,
respectively) (18, 44).
Results from the study of HumaPen Memoir are
promising as it may be speculated that children are
more likely to forget to treat themselves than adults and
they may become unsure or confused about the details
of their last insulin dose – these factors must be consid-
ered when developing a pen specifically for children.
The results of a recent usability study, involving
children, their parents, and HCPs treating children,
showed a strong preference for a new paediatric
insulin pen with a simple memory function [NovoPen
Echo® (Novo Nordisk A/S)] compared with two other
marketed insulin pens without a memory function
[HumaPen® Luxura™ HD (Eli Lilly and Company)
and NovoPen® Junior (Novo Nordisk A/S)]. In
particular, the memory function scored highly for
meeting participants’ needs and being easy to use (45).
However, it should be noted that NovoPen Echo
can provide details of only the most recent dose
administered, while HumaPen Memoir can provide
details of the 16 preceding doses. The Innovo(R)
(Novo Nordisk A/S) system was an insulin delivery
device that had a similar memory function to NovoPen
Echo, which showed the last dose administered and the
time elapsed since the last dose. However, the Innovo
system has been discontinued.
Insulin pen devices with a memory function designed
specifically for children may provide added security for
parents, who need to be assured that their child has
not missed a dose or received a double dose of insulin.
This is particularly important in younger children with
multiple caregivers. The consequences of double dos-
ing can lead to severe hypoglycaemia, neurological
impairments, or death if not identified and treated
rapidly (46).
Although parents may be ready to hand over the
responsibility for their child’s care to other people
(such as school staff/personal day carers or grand-
parents), it has been shown that parents worry about
their children having low blood glucose levels at school.
The consequence may be that parents give their chil-
dren insufficient insulin in the morning to try to prevent
hypoglycaemia at school (47). As there is often a lack
of adequate support and care in this environment (22,
47), the memory function of an insulin pen may be ben-
eficial for parents/caregivers because they will be able
to check if and when the child had a dose of insulin
while at school. Furthermore, parents/caregivers can
check if the dose their child received was appropriate.
Parents can also use a feature like the memory
function as a form of age-appropriate education to
teach their children about the importance of insulin
injections, dosing, and timing, which may remind and
reinforce the importance of taking medication. This
may provide the children with an increased sense of
independence, allowing them to gain confidence in their
ability to self-manage their diabetes.
Dosing accuracy
Insulin pens are known to provide more accurate dos-
ing than vials and syringes, especially when delivering
low doses of insulin, thereby improving short-term gly-
caemic control and potentially improving long-term
outcomes for people with diabetes (4, 5, 8, 13, 41).
Lteif and Schwenk (41) compared the accuracy of
insulin pens with syringes in children and demonstrated
that insulin pens were more accurate than syringes at
delivering insulin doses of <5 U. A total of 32 children
with type 1 diabetes and 16 parents of children with
type 1 diabetes (all of whom measured out the insulin
doses) were included in the study. In total, 24 children
(mean age: 14.1 yr) were on MDI and were familiar with
both insulin pens and vials/syringes, and 24 children
(mean age: 9.8 yr) administered a mixture of regular
and Neutral Protamine Hagedorn insulin via syringe
only (16 parents routinely drew up their child’s insulin
dose in this group and were therefore included in the
study). The accuracy and precision of the doses (morn-
ing doses measured three times from vials/syringes or
cartridges containing radio-labelled glucose and saline)
were determined by scintillation spectroscopy. In this
non-randomised study, the absolute error for doses
<5 U with insulin syringes [Becton Dickinson and Co
U100 (BD, Franklin Lakes, NJ, USA) and Terumo®
U100 (Somerset, NJ, USA) syringes] was significantly
greater than with pen devices [AutoPen® (Owen Mum-
ford Ltd, Oxford, UK) and NovoPen 1.5]: 9.9 ± 2.4%
with syringes vs. 4.9 ± 1.6% with pen devices, p < 0.01.
For doses >5 U, the absolute error with syringes was
comparable to that of insulin pens (3.2 ± 0.6% vs.
2.2 ± 0.4%, respectively). This was a small study that
employed scintillation technology instead of weight
measurement (actual insulin was not used); however, it
was the first study to compare the accuracy of syringes
vs. insulin pens in children.
A study by Gnanalingham et al. also compared the
accuracy of insulin pens with syringes. The 1, 2, 5,
and 10 U insulin doses were drawn up by one
investigator (five each of the Becton Dickinson pen and
the NovoPen) and five paediatric nurses (using 30 U
syringes) at a paediatric diabetes clinic (8). The insulin
dose was deposited onto a polystyrene container and
weighed immediately using an analytical balance. The
percentage errors for all doses studied were significantly
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lower for the Becton Dickinson pen (3%) and NovoPen
(4%) than for the syringes (9%), p < 0.0001. This was
also true for the smaller insulin doses of 1, 2, and 5 U
(p < 0.01). In general, the insulin pens underdosed;
however, the nurses had a tendency to overdose the
small insulin doses with the 30 U syringe. This study
was also small, uncontrolled, and non-randomised,
and compared syringe doses drawn up by five different
nurses, thus potentially introducing error. However, it
is one of the few studies that have looked at accuracy
relating specifically to insulin pen use in children.
Such findings are important as there is a need
for accurate and fine-tuned dosing in the paediatric
population which may require small doses of insulin.
Insulin pens that dispense half-increment doses, such
as BerliPen® Junior (Berlin-Chemie AG, Berlin,
Germany), HumaPen Luxura HD, and NovoPen
Junior may therefore be beneficial in this patient
group (48). Insulin sensitivity also differs between
patient subgroups, exemplified by insulin pump stud-
ies showing that younger children (≤6 yr) require
smaller doses of insulin/kg compared with older chil-
dren (>6 yr) (49, 50). This emphasises the importance
of accurate and convenient insulin delivery devices that
can tailor dosing according to the requirements of all
paediatric age groups.
For patients receiving MDI, the accuracy of the
insulin pen device is essential for continued confidence
in treatment. As the principal aim of diabetes man-
agement is to achieve adequate glycaemic control and
reduce the long-term complications of hyperglycaemia,
dose accuracy and precision should be the first consid-
eration when choosing an insulin pen (4). Although
half-increment dosing may be more important for
bolus administration of rapid-acting insulin, highly
insulin-sensitive young children may also benefit from
half-increment dosing with respect to administration
of basal insulin. If a patient/caregiver is certain that
the pen device is delivering insulin in accurate doses, it
may help to improve adherence to treatment. Studies
in adults and adolescents with diabetes show that
improving adherence is associated with improved
HbA1c levels, whilst decreasing the incidence of
hypoglycaemia and the number of hypoglycaemia-
associated hospital and physician visits (14, 24).
Of the insulin pens currently available that provide
insulin in half-unit increments, none have a memory
function, a feature that is also highly important for the
paediatric population, as discussed previously.
Design aspects
An insulin pen for children should be suitable for
small hands as children will be required to perform
certain functions, including dialling the dose, checking
the selected dose, pulling off the needle cap, pressing
the injection button, and replacing the cap (21). The
ability to self-inject insulin may depend on the size
of the device, especially in small children; therefore,
such a device should be relatively small, slim, and
lightweight for portability, simplicity, and ease of han-
dling. If the pen device is the correct size for the paedi-
atric population, it will be easy to operate and therefore
may improve acceptance of and adherence to treatment
regimens, which may aid in promoting self-care.
In the above-mentioned study (45), NovoPen Echo
received the most favourable rating for design and
overall appearance compared with HumaPen Luxura
and NovoPen Junior. Child-friendly coverings on
insulin pens are more likely to encourage children
to use their insulin pen devices and reduce the embar-
rassment of performing injections. This may aid in
promoting adherence to treatment. Different colours
of pen devices and/or the use of ‘skins’ (i.e., decora-
tive/protective covers typically used for mobile phones
and MP3 players) allows easy differentiation in case
different types of insulin are used in identical devices,
which may reduce the risk of patients administering the
wrong type of insulin (48). This feature would be espe-
cially advantageous for children using different kinds
of insulin (e.g., basal and bolus).
Other insulin delivery devices
Insulin pumps
Unlike insulin pens, continuous subcutaneous insulin
infusion (CSII) or insulin pump therapy mimics the
physiological delivery of insulin by using a portable
electromechanical pump to infuse insulin at a slow,
basal rate over 24 h. In addition, insulin pumps also
have a memory function; it is possible to download
details of all doses administered during the previous
month or more (49). In this regard, the functionality is
therefore not comparable to insulin pen devices. Insulin
pump therapy is recommended as a possible treatment
for children and adolescents with type 1 diabetes if
treatment with MDI is not practical or not considered
appropriate (51), for example, if HbA1c is persistently
above the individual goal, hypoglycaemia is a major
problem or quality of life needs to be improved (16). It
is also a feasible mode of insulin therapy in very young
children, and is increasingly used from the onset of
diabetes in this age group.
An increasing number of studies have shown a ben-
eficial effect on glycaemic control with CSII compared
with MDI (52–57). In addition, observational trials in
children have shown a decrease in the rate of severe
hypoglycaemic episodes with CSII, despite decreas-
ing HbA1c values (55, 58–60). Furthermore, evidence
indicates that quality of life and patient satisfaction
with CSII therapy are at least equal to or greater than
that achieved with MDI (61–64).
522 Pediatric Diabetes 2011: 12: 518–526
Insulin pens for children
However, CSII is not the preferred solution for all
children; success with a pump requires proactivity,
commitment, and motivation which may be lacking
in this patient group and their support structure. A
multidisciplinary staff/centre is required to utilise the
full potential of CSII treatment (65). Also, young chil-
dren are unable to manage their own treatment and
may need parental support to adjust pump settings.
In many schools, teachers and school nurses may be
reluctant to use insulin pumps and refuse to help young
children who are receiving CSII therapy (47). In some
situations, the parent and paediatric diabetes team
have to provide time-consuming training sessions for
school staff before allowing a young child using an
insulin pump to attend school. When adolescents use
pump therapy, it is not uncommon for them to for-
get to administer bolus insulin before/after eating a
meal (27). Besides, children and adolescents tend to eat
irregularly, and missed bolus insulin doses may coun-
terbalance the advantage of the basal insulin replace-
ment offered by CSII (25). Indeed, parents play a key
role in CSII management (66) and lack of support for
parents or proper training may prevent improvements
in glucose control. Despite insulin pumps improving
adherence to medication, they tend to be expensive and
hence less accessible to some patients (19).
Subcutaneous indwelling catheters/injection ports
Subcutaneous indwelling catheters/injection ports,
such as Insuflon® (Unomedical, Roskilde, Denmark)
and I-port® (Patton Medical Devices, Austin, TX,
USA), were originally devised to overcome problems
with injection pain at the onset of diabetes. Insuflon
is inserted and rests against the skin while the I-port
requires insertion at a 90◦ angle. Both devices have a
dead space (the hollow inside that will be filled with
insulin with the first injection) of approximately 0.5 U
of 100 U/mL, which can be added to the first dose
after replacement. They can be used with both pens
and syringes, even for administering small doses as
low as 0.5 U. For a review of the use of indwelling
catheters, see reference (67). Insuflon is inserted in the
abdomen using a topical local anaesthetic cream (68).
Insuflon is used in an increasing number of centres
for the introduction of MDI and its use does not
affect metabolic control (69). In children who have
problems using injections, HbA1c has been decreased
by using Insuflon (70). Patients who dislike injections
may therefore benefit from using Insuflon as it may
help to improve adherence to medication.
Jet injectors
A jet injector uses very high pressure to form a thin jet
stream of insulin that penetrates the skin. The insulin
is absorbed quickly and glucose control achieved using
this method can equal that achieved by an insulin
pump (71, 72). Jet injectors have been reported to
decrease injection pain (73), but this finding has been
contradicted in other studies (74, 75). Bleeding, bruis-
ing, and delayed pain after the injection have been
described (74).
Conclusions and future directions
The incidence of type 1 diabetes in the paediatric pop-
ulation is a growing concern, and the development of
adequate treatment to maintain lower blood glucose
targets is of paramount importance. As a consequence,
demand for insulin delivery devices that are simple,
accurate, and tailored for the paediatric population
will also increase.
Insulin pens are well established as a delivery device
in children and adults with diabetes, and offer improve-
ments in adherence, freedom, and flexibility over more
conventional means of administration using syringes.
Further advances in pen technology are necessary to
improve upon these features and there is a continued
drive to develop pens that are specifically targeted at
children.
Memory functions in insulin delivery devices have
much to offer. Clinical experience gained from the use
of insulin pumps has shown benefits in the ability to
download details of all doses administered during the
previous month or longer. We anticipate that develop-
ing a similar memory function in insulin pens should
help to improve the long-term management of diabetes
in the future.
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